AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
370.07B
Market cap370.07B
Price-Earnings ratio
103.28
Price-Earnings ratio103.28
Dividend yield
3.22%
Dividend yield3.22%
Average volume
5.65M
Average volume5.65M
High today
High today
Low today
Low today
Open price
$210.44
Open price$210.44
Volume
658.00
Volume658.00
52 Week high
$244.81
52 Week high$244.81
52 Week low
$180.25
52 Week low$180.25

Stock Snapshot

With a market cap of 370.07B, AbbVie(ABBV) trades at $209.66. The stock has a price-to-earnings ratio of 103.28 and currently yields dividends of 3.2%.

During the trading day, AbbVie(ABBV) stock saw an opening price of $210.44, a peak of —, and a bottom of —.

Trading activity shows a volume of 658, compared to an average daily volume of 5.65M.

The stock's 52-week range extends from a low of $180.25 to a high of $244.81.

The stock's 52-week range extends from a low of $180.25 to a high of $244.81.

ABBV News

24/7 Wall St. 4d
Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbbVie wasn't one of them. Get them here FREE . Income investors are increasingly abando...

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now
TipRanks 4d
AbbVie price target lowered to $235 from $236 at Evercore ISI

Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $235 from $236 and keeps an Outperform rating on the shares. Unlock hedge fund-level data and...

Simply Wall St 4d
We Think You Can Look Beyond AbbVie's Lackluster Earnings

The market was pleased with the recent earnings report from AbbVie Inc. ( ), despite the profit numbers being soft. Our analysis suggests that investors may hav...

We Think You Can Look Beyond AbbVie's Lackluster Earnings

Analyst ratings

73%

of 33 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

More ABBV News

TipRanks 5d
AbbVie Quietly Expands Its Obesity Bet With New ABBV-295 Trial

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...

TipRanks 5d
AbbVie’s ABBV-951 Parkinson’s Extension Study Completes, Setting Up Key Long-Term Safety Readout

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...

TipRanks 5d
Regenxbio reports Q1 EPS ($1.72) vs. 12c last year

Reports Q1 revenue $6.4M vs. $89M last year. “REGENXBIO (RGNX) enters a transformative year with positive momentum, reaching significant late-stage milestones t...

Simply Wall St 5d
Assessing AbbVie Valuation After Recent Share Price Pullback And Mixed Performance

Advertisement What AbbVie’s Recent Performance Tells You AbbVie (ABBV) has drawn investor attention after a mixed recent run in the stock. The share price is...

Assessing AbbVie Valuation After Recent Share Price Pullback And Mixed Performance
TipRanks 7d
AbbVie Shareholders Back Directors, Maintain Governance Structure

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.